Alligator Bioscience

Alligator Bioscience is a clinical-stage biotechnology company developing targeted tumor immunotherapy antibody drugs. Alligator Bioscience's growing pipeline includes five clinical and preclinical candidate drugs (ADC-1013, ATOR-1015, ATOR-1017, ALG.APV-527, and ATOR-1144). ADC-1013 (JNJ-7107) has been licensed to Janssen Biotech, a subsidiary of J&J, for global development and commercialization.